Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05182164
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:12.638435+00:00
Published At
2025-10-07T00:00:00+00:00
Record Updated At
2025-10-07
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Soft Tissue Sarcoma Adult", "Advanced Soft-tissue Sarcoma", "Ewing Sarcoma", "Osteosarcoma", "Undifferentiated Pleomorphic Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-10-07"
protocolSection.identificationModule.nctId
"NCT05182164"
protocolSection.identificationModule.officialTitle
"Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Soft Tissue Sarcoma Adult (protocolSection.conditionsModule.conditions)
  • Advanced Soft-tissue Sarcoma (protocolSection.conditionsModule.conditions)
  • Ewing Sarcoma (protocolSection.conditionsModule.conditions)
  • Osteosarcoma (protocolSection.conditionsModule.conditions)
  • Undifferentiated Pleomorphic Sarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.